With seizure drug held up at FDA again, Aque­s­tive re­places long­time CEO

The C-suite mu­si­cal chairs re­ver­ber­at­ing through biotech the last few months con­tin­ued Tues­day af­ter­noon with an­oth­er small cap com­pa­ny an­nounc­ing a tran­si­tion at the top.

Long­time Aque­s­tive Ther­a­peu­tics CEO Kei­th Kendall will leave the com­pa­ny ef­fec­tive im­me­di­ate­ly, the biotech an­nounced late Tues­day, bring­ing an end to his sev­en-and-a-half year tenure. Kendall will re­main a con­sul­tant through the end of the year and be re­placed by Daniel Bar­ber, the com­pa­ny’s COO since May 2019, on a per­ma­nent ba­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER